Malignant Neoplasm of Prostate Clinical Trials

4 recruiting

Malignant Neoplasm of Prostate Trials at a Glance

11 actively recruiting trials for malignant neoplasm of prostate are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Cleveland, Freiburg im Breisgau, and Augsburg. Lead sponsors running malignant neoplasm of prostate studies include Case Comprehensive Cancer Center, Azienda Ospedaliero-Universitaria Careggi, and Angela Y. Jia, MD PhD.

Browse malignant neoplasm of prostate trials by phase

Treatments under study

About Malignant Neoplasm of Prostate Clinical Trials

Looking for clinical trials for Malignant Neoplasm of Prostate? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Neoplasm of Prostate trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Neoplasm of Prostate clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting

PROCARE - PROstate Cancer Real World Evidence Registry

Prostate CancerNon-metastatic Castration-resistant Prostate CancerBiochemical Recurrence of Malignant Neoplasm of Prostate
UroTrials Company (GmbH)5,000 enrolled53 locationsNCT06835218
Recruiting
Not Applicable

Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate Cancer

Malignant Neoplasm of Prostate
Case Comprehensive Cancer Center80 enrolled1 locationNCT04556045
Recruiting
Phase 1Phase 2

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

Malignant Neoplasm of ProstateLocally Advanced Prostate Cancer
Angela Y. Jia, MD PhD45 enrolled1 locationNCT06574880
Recruiting
Phase 2

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

Prostate CancerMalignant Neoplasm of ProstateSecondary Malignant Neoplasm of Prostate
Case Comprehensive Cancer Center200 enrolled2 locationsNCT06150417
Recruiting

MRI-Guided Cryoablation for Focal Native Prostate Cancer

Primary Malignant Neoplasm of Prostate (Diagnosis)
Mayo Clinic100 enrolled1 locationNCT04797039
Recruiting

A Prospective, Bicentric Evaluation of Fluciclovine PET-imaging in Patients with Prior Negative or Inconclusive PSMA-ligand PET

Biochemical Recurrence of Malignant Neoplasm of Prostate
Technical University of Munich94 enrolled2 locationsNCT06859203
Recruiting

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Biochemical Recurrence of Malignant Neoplasm of ProstateProstate Cancer After a Radical TreatmentBiochemical Persistence of Prostate Cancer
Heinrich-Heine University, Duesseldorf250 enrolled1 locationNCT06657131
Recruiting
Phase 3

68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients

Prostate CancerBiochemical Recurrence of Malignant Neoplasm of ProstateBCR Prostate Carcinoma
Telix Pharmaceuticals (Innovations) Pty Limited110 enrolled8 locationsNCT05847348
Recruiting
Early Phase 1

68Ga-AAZTA-093 PET/CT: First-in-human Study

Malignant Neoplasm of Prostate
First Affiliated Hospital of Fujian Medical University30 enrolled1 locationNCT06437496
Recruiting
Phase 2

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy

Urologic CancerBiochemical Recurrence of Malignant Neoplasm of Prostate
Prof. Dr. med. Christian Gratzke49 enrolled1 locationNCT04931979
Recruiting

PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE

Prostate CancerProstate AdenocarcinomaProstate Cancer Recurrent+1 more
Azienda Ospedaliero-Universitaria Careggi180 enrolled1 locationNCT05022914